Non-pegylated liposomal doxorubicin triple combination therapy

Details Non-pegylated liposomal doxorubicin triple combination therapy Non-pegylated liposomal doxorubicin triple combination therapy

A - Human Necessities

61

K

A61K 9/127 (2006.01) A61K 31/337 (2006.01) A61K 31/7036 (2006.01) A61K 39/395 (2006.01)

Patent

CA 2757986

The present invention relates to a method for treating metastatic breast cancer in an individual comprising administering to an individual in need thereof a dosing regimen which comprises administering to the individual nonpegylated liposomal doxorubicin, a taxane and a HER2/neu receptor antagonist, wherein the individual previously has been administered an anthracycline.

La présente invention porte sur un procédé de traitement d'un cancer du sein métastasique dans un individu comprenant l'administration à un individu en ayant besoin d'un régime posologique qui comprend l'administration à l'individu de doxorubicine liposomale non pégylée, d'un taxane et d'un antagoniste du récepteur HER2/neu, l'individu ayant fait l'objet auparavant d'une administration d'anthracycline.

Affiliated with

Also associated with

Rating

Non-pegylated liposomal doxorubicin triple combination therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Non-pegylated liposomal doxorubicin triple combination therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Non-pegylated liposomal doxorubicin triple combination therapy will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1721969